Logo

Takeda to Advance FIN-524 Development Program in Ulcerative Colitis

Share this
Takeda to Advance FIN-524 Development Program in Ulcerative Colitis

Takeda to Advance FIN-524 Development Program in Ulcerative Colitis

Shots:

  • Takeda will lead the development of FIN-524/TAK-524 to treat UC prior to the start of its clinical program & will leverage its expertise in IBD throughout the development process
  • Finch plans to provide ongoing technical support through the P-I trial of FIN-524/TAK-524 in the same indication. The companies will continue to advance the program for CD
  • In 2017- Takeda & Finch collaborated to develop TAK-524 for IBD under which Finch has received $10M upfront- $4M in milestone- and is eligible to receive an additional ~ $176M as additional milestones along with royalties on WW net sales of the therapy. Finch was primarily responsible for early-stage development activities through P-II study

   Ref: Finch Therapeutics | Image: Finch

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions